The National Cancer Institute (NCI) invites applications for research projects proposing the development of highly innovative cancer relevant technologies. Technology encompasses methods and tools that enable research, including, but not limited to, instrumentation, techniques, and devices. Technology is distinct from resources such as databases, reagents, and tissue repositories. This initiative will employ separate discovery (R21) and development (R33) awarding mechanisms. The R21 application will emphasize the high risk, high innovation feasibility phase and potential impact. The development (R33) phase application will have to contain proof of the feasibility of the proposed technology. Under this RFA, applicants must submit either an R21 application or a fully developed R33 application, according the guidelines below. The R21 may not exceed $100,000 direct costs per year for up to 2 years. The proposed R33 project period may be up to a maximum of 3 years. This program will run in parallel with a program of identical scientific scope CA-05-006 that will utilize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms.

• Release Date: December 17, 2003
• Letter of Intent Receipt Date(s): January 16, 2004; May 17, 2004; September 17, 2004
• Application Receipt Date(s): February 17, 2004; June 17, 2004; October 18, 2004
• Contact: Contact: Barbara Y. Croft, Ph.D. (bc129b@nih.gov) at 301-496-9531

See full description in NIH Guide: CA-05-002